Axim Biotechnologies Inc. (OTCMKTS: AXIM) Appoint Kelly Nichols To The Board, Medipharm Labs Corp (OTCMKTS: MEDIF) Appoints New CEO

Axim Biotechnologies Inc. (OTCMKTS: AXIM) has appointed Kelly K Nichols to its Medical Advisory Board. Nichols joins the company’s other Advisory Board members, including Laura Periman, Henry Perry, and Chairperson Joseph Tauber.

Nichols appointed to Axim board 

CEO John Huemoeller II said, “We are rapidly increasing the synergistic value of our Medical Advisor Board by constructing it strategically. Optometrists are the US’ primary eye health care providers and the frontline of its eye and vision care. Accordingly, AXIM must communicate the benefit and accuracy of our DED diagnostic tests with the nation’s optometrists in a collaboration to enable increased diagnosis of this often-undiagnosed disease so its millions of sufferers can obtain the care they need.”

Nichols is a Dean at The University of Alabama at Birmingham. She is a leading dry eye disease expert that has been on editorial boards of “The Ocular Surface” and “Optometry and Vision Science” journals. Nichols has researched meibomian gland dysfunction, dry eye diagnostics and therapeutics, dry eye in menopause, lipidomics, and tear proteomics.

Medipharm new appoints CEO 

Medipharm Labs Corp (OTCMKTS: MEDIF) has announced that Bryan Howcroft has joined the company as a Director and Chief Executive Officer effective November 15, 2021. Howcroft has over 20 years of experience in several industries, including healthcare imaging, manufacturing, and medical devices.

Chairman Medipharm Labs Chris Taves said, “As a pharmaceutical company specialized in precision-based cannabinoids, MediPharm Labs was seeking a CEO who could lead the charge on increased sales in the medical and consumer markets. We found that CEO in Bryan, who has the experience and expertise in growing medical industry business coupled with knowledge on effective operational management. Bryan is a tenacious leader who believes in a customer-first approach that will be critical for MediPharm to scale our business, and will bring a healthy level of urgency to pursue the many opportunities that lie ahead.”